Opal Wealth Advisors LLC Buys 226 Shares of Johnson & Johnson (NYSE:JNJ)

Opal Wealth Advisors LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 13.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,875 shares of the company’s stock after purchasing an additional 226 shares during the period. Opal Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $304,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Heartwood Wealth Advisors LLC raised its stake in shares of Johnson & Johnson by 112.0% in the first quarter. Heartwood Wealth Advisors LLC now owns 8,757 shares of the company’s stock worth $1,385,000 after purchasing an additional 4,627 shares during the last quarter. Duncan Williams Asset Management LLC bought a new position in Johnson & Johnson during the 1st quarter valued at about $512,000. Cullen Investment Group LTD. boosted its holdings in shares of Johnson & Johnson by 2.7% during the 1st quarter. Cullen Investment Group LTD. now owns 68,585 shares of the company’s stock valued at $10,818,000 after acquiring an additional 1,793 shares during the last quarter. CWM LLC raised its holdings in shares of Johnson & Johnson by 8.3% during the first quarter. CWM LLC now owns 386,640 shares of the company’s stock valued at $61,163,000 after purchasing an additional 29,778 shares during the last quarter. Finally, Davis Capital Management lifted its position in Johnson & Johnson by 6.2% during the first quarter. Davis Capital Management now owns 9,144 shares of the company’s stock valued at $1,443,000 after purchasing an additional 531 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on JNJ shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Thursday, October 10th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Daiwa America cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. TD Cowen reduced their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Finally, Morgan Stanley raised their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a report on Thursday, July 18th. Six analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $174.31.

Johnson & Johnson Trading Up 1.6 %

Shares of Johnson & Johnson stock opened at $164.14 on Wednesday. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The company has a market capitalization of $395.02 billion, a P/E ratio of 10.23, a P/E/G ratio of 2.65 and a beta of 0.52. The company has a fifty day moving average of $162.70 and a 200 day moving average of $154.52.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter last year, the business posted $2.80 earnings per share. The firm’s revenue was up 4.3% on a year-over-year basis. On average, sell-side analysts anticipate that Johnson & Johnson will post 10 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.